Kymab, a UK biopharma developing antibody-based therapeutics, has appointed Simon Sturge as its new CEO.
He succeeds David Chiswell, who remains a scientific adviser to the company.
“We are delighted that such an experienced leader as Simon will lead Kymab to its next stage of growth,” said Martin Nicklasson, Non-Executive Chair.
He added: “This appointment is part of Kymab’s strategy to position itself for long-term success, building on the incredibly strong R&D foundation of the company.”
Mr Sturge joins Kymab from Merck KGaA, where he was Executive Vice President Global Strategy, Business Development & Global Operations.
Previously, he was Chief Operating Officer of Merck Healthcare, responsible for company’s global commercial and manufacturing operations.
Prior to joining Merck KGaA, he served as Corporate Senior Vice President, Biopharmaceuticals at Boehringer Ingelheim, where he had responsibility for the research, development and commercialisation of the company’s global biosimilar portfolio.
Before that, he held CEO roles at a number of healthcare companies including Celltech Biologics, and he served as founder and CEO of Ribotargets, which was acquired by British Biotech and subsequently renamed Vernalis.